Van Kooten C , Banchereau J . CD40-CD40 ligand . J Leuk Biol2000; 67: 2-17 .
2.
Gerritse K , Laman JD , Noelle RJ et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis . Proc Natl Acad Sci USA1996; 93: 2499-2504 .
3.
Durie FH , Aruffo A , Ledbetter J et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of Graft-vs-Host Disease . J Clin Invest1994; 3: 1333-1338 .
4.
De Jong YP , Comiskey M , Kalled SL et al. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration . Gastroenterology2000; 119: 715-723 .
5.
Durie FH , Fava RA , Foy TM et al. Prevention of collagen-induce arthritis with an antibody to gp39, the ligand for CD40 . Science1993; 261: 1328-1330 .
6.
Early GS , Zhao W , Burns CM . Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black X New Zealand white mice. Response correlates with the absence of an anti-antibody response . J Immunol1996; 157: 3159-3164 .
7.
Mohan C , Shi Y , Laman JD , Datta SK . Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis . J Immunol1995; 154: 1470-1480 .
8.
Kalled SL , Cutler AH , Datta SK , Thomas DW . Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function . J Immunol1998; 160: 2158-2165 .
9.
Kalled SL , Cutler AH , Ferrant JL . Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis . Lupus2001; 10: 9-22 .
10.
Russell JQ , Mooney T , Cohen PL et al. Anti-CD40L accelerated renal disease and adenopathy in MRL-lpr mice in parallel with decrease thymocyte apoptosis . J Immunol1998; 161: 729-739 .
11.
Datta SY . Mechanisms of the pathogenic autoimmune response in lupus. In: Kammer GM , Tsokos GC (eds) Lupus: Molecular and Cellular Pathogenesis. Humana Press: Totowa, New Jersey , 1999.
